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Abstract
Background: Human papillomavirus (HPV) vaccines are widely available and there have been studies exploring
their potential clinical impact and cost-effectiveness. However, few studies have compared the cost-effectiveness
among the 2 main vaccines available - a bivalent vaccine against HPV 16/18, and a quadrivalent vaccine against 6/
11/16/18. We explore the cost-effectiveness of these two HPV vaccines in tropical Singapore.
Methods: We developed a Markov state-transition model to represent the natural history of cervical cancer to
predict HPV infection, cancer incidence, mortality, and costs. Cytologic screening and treatment of different
outcomes of HPV infection were incorporated. Vaccination was provided to a cohort of 12-year old females in
Singapore, followed up until death. Based on available vaccines on the market, the bivalent vaccine had increased
effectiveness against a wider range of HPV types, while the quadrivalent vaccine had effectiveness against genital
warts. Incremental cost-effectiveness ratios (ICER) compared vaccination to no-vaccination, and between the two
vaccines. Sensitivity analyses explored differences in vaccine effectiveness and uptake, and other key input
parameters.
Results: For the no vaccination scenario, 229 cervical cancer cases occurred over the cohort’s lifetime. The total
discounted cost per individual due to HPV infection was SGD$275 with 28.54 discounted life-years. With 100%
vaccine coverage, the quadrivalent vaccine reduced cancers by 176, and had an ICER of SGD$12,866 per life-year
saved. For the bivalent vaccine, 197 cancers were prevented with an ICER of $12,827 per life-year saved. Comparing
the bivalent to the quadrivalent vaccine, the ICER was $12,488 per life-year saved. However, the cost per QALY
saved for the quadrivalent vaccine compared to no vaccine was $9,071, while it was $10,392 for the bivalent
vaccine, with the quadrivalent vaccine dominating the bivalent vaccine due to the additional QALY effect from
reduction in genital warts. The overall outcomes were most sensitive to vaccine cost and coverage.
Conclusion: HPV vaccination is a cost-effective strategy, and should be considered a possible strategy to reduce
the impact of HPV infection.
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Background
Cervical cancer is the second most common cancer in
women worldwide [1], affecting 500,000 women annually
and resulting in more than 250,000 deaths [2]. In Singa-
pore, despite decreasing incidence of cervical cancer as a
result of regular cytological screening, it remains a com-
mon gynaecological cancer [3], with 200 cases and about
100 deaths annually [3,4].
Human papillomavirus (HPV) infection is the main
cause of cervical cancer. There are more than 150 differ-
ent strains of HPV but only about 15 are high-risk
oncogenic strains for cervical cancer. Of these, HPV
types 16 and 18 account for about 70% of all cervical
cancer cases, while the other oncogenic strains account
for the rest [5-7]. Two prophylactic HPV vaccines, a
bivalent vaccine which targets HPV 16/18, and a quadri-
valent vaccine which targets 6/11/16/18, are widely
available. Both vaccines have shown to be highly effec-
tive in clinical trials and economic studies of HPV
vaccines have found them to be cost-effective in various
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universal vaccination of women with the HPV vaccine.
Before any universal vaccine implementation, it is
important for policymakers to understand the long-term
benefits (beyond the time horizon of clinical trials) of
the vaccine by using mathematical modelling in a deci-
sion-analytic framework [9-17]. Extending previous stu-
dies of HPV vaccination, we compare the status quo of
cervical cancer screening only and vaccination with a
quadrivalent or bivalent vaccine in addition to baseline
screening. This allowed us to determine the cost-effec-
tiveness of vaccination over the current screening prac-
tices, and the incremental cost-effectiveness of one
vaccine over the other.
Methods
We developed a deterministic Markov state-transition
model based on the natural history of HPV infection
and cervical cancer in the tropical South-East Asian
city-state Singapore (Figures 1). We assumed that the
natural history is relatively long, therefore the cycles
were annual [18,19]. The model was performed on a
hypothetical cohort of women in Singapore who turned
12 years old in 2008, which is the typical age of HPV
vaccination. This amounted to a mid-year female popu-
lation of 25,000 [20] and the model followed this cohort
until death - 88 cycles, assumed to correspond to the
time needed until everyone has died. We assumed that
sexual activity and hence HPV infection only occurred
after age 12.
Life expectancies and annual mortality rates for the
cohort were obtained from the Singapore Department of
Statistics [20]. For the input variables (Table 1)
[4,18-29], we obtained data from local sources where
available, including disease incidence and costs of inter-
ventions and outcomes. Most studies on disease evolu-
tion and transition between different disease states were
p e r f o r m e db yaf e wl a r g ei n t e r n a t i o n a ls t u d i e s-w e
therefore relied on these to obtain input parameters.
The variables were calibrated to the local setting based
on local incidence data.
Transition probabilities
HPV infection progresses to cervical intraepithelial neo-
plasia (CIN), the precursor of cervical cancer. The usual
progression is from CIN 1 to CIN 2, CIN 3, and persis-
tent forms of the latter 2 CIN stages. CIN 2,3 is grouped
together due to similar outcomes and management,
while the persistent forms are direct precursors of cervi-
cal cancer. Cervical cancers are divided into 4 prognos-
tic stages 1 to 4. Each progressive stage is associated
with poorer prognosis, lower treatment success rates,
and higher recurrence and relapse rates. The transition
probabilities for disease progression were obtained from
previously published sources (Table 1). To account for
uncertainty, we performed wide sensitivity analyses.
Screening
In Singapore, recommended screening for cervical can-
cer starts at age 25 years for women who have ever had
sexual intercourse and at 3 yearly intervals if previous
smears were negative, until the age of 69 if all smears
are negative. In 2004, a survey showed that across all
age groups, only 52% of women had their Pap smear
done in the last 3 years, but most women did not
undergo regular screening every 3 years [4]. We there-
fore assumed that Singaporean women would on aver-
age start screening at 25 years of age, and 17% of the
cohort would undergo screening each year.
We assumed that the sensitivity of PAP smears were
58% for CIN 1 and 61% for CIN2,3 [30,31]. If a smear is
abnormal, further tests including colposcopy and if
necessary biopsy are introduced as per local abnormal
pap smear guidelines [41], and treatment performed as
clinically indicated. We also assumed that once positive,
all CIN states would be confirmed by colposcopy and
biopsy, and 75% of CIN1 and 75% of CIN2, 3 cases
would comply to treatment with an efficacy of 90% [32].
Treatment
For CIN, the chance of cure is almost 100% and we
assumed a mean cost of treatment for the various CIN
stages. For cervical cancer, the chance of cure depends
on the cancer stage, while the treatment cost depends
on the treatment type. We also determined the chance
of symptoms occurring which would lead to early
Figure 1 Markov model for the history of cervical cancer
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Page 2 of 11Table 1 Vaccination, screening, cost parameters and
transition probabilities
Parameters Base
case
Ranges Source
Vaccination
Cohort size 25,000 [20]
Vaccine coverage 100% Assumption
Age at vaccination 12
Vaccine efficacy* -
bivalent vaccine
87.2% 70%-95% [21,22]
Vaccine efficacy* -
quadrivalent vaccine
78.8% 70%-95% [23]
Duration of efficacy Lifetime 5 years to lifetime Assumption
Vaccine waning + booster None 5, 10, 20 years Assumption
Screening
Screening age range 25-65 [4]
Screening interval every 3
years
[4]
Percentage screened per
year
17% 10-20 Estimated
Cytology sensitivity to
detect CIN1
0.58 none [18,19]
Cytology sensitivity to
detect CIN2/3
0.61 none [18,19]
Compliance to CIN1
treatment
75% 50%-100% Assumption
Compliance to CIN2/3
treatment
75% 50%-100% Assumption
Cancer detection rate Low High
Probability Of symptons
CC1
0.075 0.185
Probability Of symptons
CC2
0.113 0.3
Probability Of symptons
CC3
0.3 0.75 [24,25]
Probability Of symptons
CC4
0.45 0.8
Cost, SGD$ (2008) (-20%/+50%)
except vaccine
cost (200-400)
Vaccine cost per
vaccinated woman,
bivalent vaccine #
400
Vaccine cost per
vaccinated woman,
quadrivalent vaccine#
400 Assumption
Cytology test^ 40
Colposcopy and Biopsy^ 207
CIN 1 treatment 1,105
CIN 2/3 treatment 1,480
Stage 1 Cancer treatment
cost
9,388 Singapore
public sector
hospitals
Stage 2 Cancer treatment
cost
9,765
Table 1 Vaccination, screening, cost parameters and tran-
sition probabilities (Continued)
Stage 3 Cancer treatment
cost
9,765
Stage 4 Cancer treatment
cost
11,047
Genital warts 750
Discounting
Costs, Outcomes 3%, 3% (0%-5%) Assumption
Transition Probabilities
Well to HPV 0.05 0-0.2
HPV to clearance 0.4 0.29-0.55
HPV to CIN1 0.05 0.014-0.14 [18,19,26]
CIN1 clearance 0.4 0.24-0.5
CIN1 to CIN2/3 0.09 0.02-0.32
CIN2/3 clearance 0.25 0.01-0.45
CIN2/3 to persistent CIN2/
3
0.11 0.03-0.20
Persistent CIN2/3 to
Cancer stage 1
0.05 0.001-0.15
Cancer stage 1 to Cancer
stage 2
0.22 0.11-0.4
Cancer 1 to cancer cured 0.84 0.63-0.98
Cancer stage 1 to Cancer
stage 3
0.24 0.12-0.5
Cancer 2 to cancer cured 0.66 0.49-0.83
Cancer stage 3 to Cancer
stage 4
0.24 0.12-0.8
Cancer 3 to cancer cured 0.38 0.28-0.48 [21,22,24-26]
Cancer 4 to cancer cured 0.11 0.08-0.14
Detected CIN1 to well 0.9 0.8-1
Detected CIN1 to
Detected CIN2/3
0.09 0.02-0.32
Detected CIN2/3 to Well 0.9 0.8-1
Detected CIN2/3 to
Detected PCIN2/3
0.11 0.03-0.20
Detected PCIN2/3 to
Cancer 1
0.05 0.001-0.15
Mortality of cervical
cancer
0.11
Cervical Warts
Effectiveness of
vaccination against warts
0.90 [27,28]
Cost of treatment 750
Well to low risk HPV 0.050
Low risk HPV to well 0.500
Low risk HPV to CIN1 low
risk
0.036
Low risk HPV to warts 0.027
Warts to well 0.875
CIN1 low risk to well 0.500
CIN1 low risk to detected
CIN 1 low risk
0.099
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and costs based on local data obtained from hospitals.
As local data on survival rates together with disease
transition probabilities were not available, and overall
survival rates in Singapore were comparable to devel-
oped countries [42], we used available cancer survival
rates from similar developed countries [21,22]. These
survival rates were annualized across 5 years to deter-
mine overall cure rates for each year - we assumed that
those who survive beyond 5 years were cured. Once
cancer was detected, we assumed that all individuals
would undergo treatment. We did not model outcomes
of treatment as individual state transitions but attributed
an overall cost to each state.
Vaccination
In Singapore, the quadrivalent and bivalent vaccines
have been licensed since 2006 and 2007 respectively.
Vaccination remains voluntary, and privately funded
individually. To compare between the vaccines, we
assumed that the bivalent vaccine has a higher efficacy
against other non-16/18 high-risk HPV types compared
with the quadrivalent vaccine [32] using a technique
described by Debicki et al [25] and shown in Table 2.
However, the quadrivalent vaccine has additional protec-
tion against other low-risk HPV-types that cause genital
warts and CIN 1 - the bivalent vaccine is assumed to
have no such protection.
Based on recent studies, the range of protection for
non-16/18 oncogenic HPV types are between 53.0% and
68.2% for the bivalent vaccine [23,33] and 32.5% for the
quadrivalent vaccine [21]. The overall effectiveness for
the quadrivalent vaccine has been shown to be about
75% [34]. In addition, the quadrivalent vaccine has a
90% protection against HPV-types that cause genital
warts [27,28]
Base case vaccine characteristics are assumed as fol-
lows: (1) proportion of individuals protected following
immunization is 100%; (2) vaccine duration is life-long;
(3) effectiveness of both vaccines against HPV types 16/
18 are similar at 95% [23,33-40]; (4) to create fair com-
petition, we assumed that the prices of both vaccines
were equivalent and includes all vaccination costs; (5)
we did not include therapeutic benefits to vaccinated
patients already infected and assumed that the natural
disease history is unaltered; (6) we assumed that all girls
based on the coverage rate would receive the full vac-
cine course and be immunized after 1 year. We per-
formed sensitivity analyses on these assumptions.
CIN State Adjustments
For the CIN states, we had to determine the actual pro-
portion of CIN cases that are reduced by vaccination, as
not all CIN states are affected by vaccination as com-
pared to cancer. This is to allow for the reduction pro-
portion to be accurate as this will influence the costs of
the different strategies. We used a correction method
well described by Debicki et al [25] where we deter-
mined the proportion of CIN 1 and CIN2/3 cases that
were caused by non-oncogenic viruses in the no vaccine
strategy, and added these numbers to those obtained for
oncogenic viruses in the vaccination strategy (Table 2).
Genital Warts
Genital warts are another manifestation of HPV infec-
tion caused by non-oncogenic HPV viruses. Low-onco-
genic-risk HPV-6/11 is responsible for >95% percent of
genital warts [43,44]. Genital warts cause superficial
symptoms but do not result in cancer, and are therefore
a separate outcome of HPV infection.
The model for the development of genital warts is
shown in Figure 2. We assumed that low-oncogenic-risk
HPV types can either cause clinical genital warts or CIN
1. Clinical genital warts would be identified clinically
and treated. CIN 1 would be detected through the nor-
mal screening process and we assumed would be indis-
tinguishable from CIN 1 caused by oncogenic types. A
reduction in CIN 1 caused by low-oncogenic-risk HPV
types would contribute to the overall reduction in CIN
1 incidence [45].
Costs, Utility, and discounting
Costs of the various interventions and outcomes were
o b t a i n e df r o mp a t i e n t sw i t hH PV infection, CIN states,
and cervical cancer diagnosed in 2004 across public sec-
tor hospitals in Singapore (SK Tay, unpublished data).
All medical services were traced and costs collected
from hospital finance data for the following 5 years or
Table 1 Vaccination, screening, cost parameters and tran-
sition probabilities (Continued)
Detected CIN 1 low risk
to well
0.950
QALYs
Disease free 1
Genital warts 0.96 0.91-0.99 [10,25,29]
Detected CIN 0.89 0.84-0.94
Cancer detected
Stage I 0.65 0.49-0.81
Stage II 0.56 0.42-0.70
Stage III 0.56 0.42-0.70
Stage IV 0.48 0.36-0.60
Cancer cured 0.94
*Calculated, refer to Table 1b.
#including costs of implementing, administration and support for vaccination
programme
^including admininistrative cost & patient costs
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formed the analysis starting from the year 2008 and all
interventions according to technology available in 2008.
We adopted the health services perspective and included
all direct medical costs and benefits. Vaccination cost
includes the vaccine cost and related administrative fees.
All costs are represented in 2008 Singapore dollars
(2008 exchange rate, USD1: SGD1.416).
For the Quality-Adjusted Life Years (QALYs) calcula-
tions, the utility values were obtained from other devel-
oped countries as similar data was not available locally
(Table 1a). Utility for each health state, which ranged
from 1 which corresponded to complete health to 0 for
death, were multiplied by the time spent in each state.
Genital warts and detected CIN (colposcopy treatment)
was given utility values of 0.96 and 0.89 respectively
[29]. Quality values for various detected cancer stages
differed depending on the cancer stage, while cured can-
cer was slightly less than complete health [10,25].
Since the model ran over a long time-frame, costs and
benefits were translated into present values using a dis-
count factor [46-49]. Health outcomes and costs were
discounted at 3% per annum, similar to previous local
economic evaluations.
Analyses
The model was run using Excel spreadsheets (Microsoft
Corp, Redmond, WA) and @Risk (Palisade, Newfield,
NY) simulation add-in. We performed cost-benefit ana-
lysis using the costs per life-year saved with individual
economic value calculated from the net present value of
future annual earnings (earnings-equivalent for the
elderly), adjusted for age [50]. We also performed cost-
effectiveness analyses; and cost-utility analyses as not all
negative health outcomes resulted in death. The incre-
mental cost-effectiveness ratio (ICER) would be accepta-
ble if it is below the per-capita gross domestic product
(GDP) for the population. The per-capita GDP for Sin-
gapore in 2008 was $53,192.
All parameters were subject to sensitivity analysis to
determine which input variables were most important in
determining the final strategy. We performed one-way
and two-way sensitivity analyses on vaccination and
transition parameters to determine the impact of
changes in input variables. This allowed us to determine
which parameters had the highest influence on the out-
come, and would be priority areas for intervention.
Results
Base case analysis
Table 3 reports the base-case results of estimated cases,
non-discounted and discounted total costs, life-years,
and QALYs. The model estimates that approximately
86% of cervical cancer, 86% of deaths from cancer, and
Figure 2 Markov model for the history of genital warts
Table 2 Details of efficacy calculations
Source
Bivalent
vaccine
Quadrivalent
vaccine
Reduction in the
probability of HPV infection
Assumed proportion of HPV
16/18 in cervical cancer, A
74.9% 74.9% [7]
Vaccine efficacy-percent
reduction in HPV 16/18
persistent infections, B
95.0% 95.0% [23,27,28,32-40]
Assumed proportion of other
high risk HPV in cervical
cancer, C
23.4% 23.4% [7]
Vaccine efficacy-percent
reduction in other high risk
HPV persistent infections, D
68.4% 32.5% [30-32]
Calculated reduction in the
probability of HPV infection
(AxB)+(CxD)
87.2% 78.8%
Corection factor for CIN1
Percent of HPV 1618 in CIN1
cases which are caused by
oncogenic HPV, E
37.0%
Correction factor for CIN1, A-E 37.9%
Corection factor for CIN2/3
Percent of HPV 1618 in CIN2/
3 cases which are caused by
oncogenic HPV, F
52.0%
Correction
factor for CIN2/3 A-F
22.9%
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CIN 2/3 cases could be prevented by the bivalent vac-
cine vaccination. The quadrivalent vaccine avoids these
cases by 2-9% less than the bivalent vaccine. However,
the quadrivalent vaccine reduces genital warts cases by
89%. Vaccination with the bivalent or quadrivalent vac-
cine yielded 634 and 570 respectively more life years
than screening alone.
From the cost-benefit analysis, the incremental savings
is $8.23 m with the quadrivalent vaccine and $9.47 m
with the bivalent vaccine, or an advantage of $1.24 m
for the bivalent over the quadrivalent vaccine. For the
cost-effectiveness analysis, the cost per life year saved
for the quadrivalent vaccine compared to no vaccine
was $12,866, compared to $12,827 for the bivalent vac-
cine. Comparing the bivalent to the quadrivalent vac-
cine, the ICER is $12,488, showing that the bivalent
vaccine saves more lives for the cost. However, the cost
per QALY saved for the quadrivalent vaccine compared
to no vaccine was $9,071, while it was $10,392 for the
bivalent vaccine, with the quadrivalent vaccine dominat-
ing the bivalent vaccine due to the additional QALY
effect from reduction in genital warts.
Sensitivity analysis
For the sensitivity analyses, we compared 3 different out-
comes - the quadrivalent vaccine to screening alone, the
bivalent vaccine to screening alone and the bivalent vac-
cine to the quadrivalent vaccine. Table 4 shows selected
sensitivity analyses results. Decreasing vaccine coverage
while keeping vaccination costs constant (assuming that
vaccine purchases are sunk costs) increased the ICER
and decreases cost-benefit across the board, especially at
vaccine coverage levels ≤40% where vaccination is not
cost-effective. If vaccination costs can be capped to only
those who receive vaccination, then either vaccine
remains cost effective even at 20% vaccination levels.
Lowering the overall vaccinee f f i c a c yi n c r e a s e sI C E R
and decreases cost-benefit for both vaccination strate-
gies compared to no vaccination, but vaccination still
remains cost-effective even if no cross-reactivity against
low-risk HPV types is present. In the latter scenario, the
quadrivalent vaccine dominates the bivalent vaccine
even for the additional cost per life year saved, due to
the additional reduction on genital warts.
Decreasing vaccination costs for both vaccines
decreases the overall ICER and increases the cost-benefit
Table 3 Summary of estimated cases, non-discounted and discounted total costs and life-years of a single age-cohort
(n = 25,000) of 12 year old girls
Screening only Bivalent* Quadrivalent*
Cases
Cervical cancer 229 32 53
Deaths from cervical cancer 144 20 33
CIN Persistent 2n3 detected 2,073 294 480
CIN 2n3 detected 382 135 168
CIN 1 detected 2,109 1,127 1,293
Genital warts 4,126 4,126 447
NON-DISCOUNTED
Total costs 21,150,496 25,020,340 22,822,396
Vaccine costs - 10,000,000 10,000,000
Screening costs 11,006,014 9,949,324 10,078,234
CIN1 treatment costs 2,330,522 1,245,203 1,292,796
CIN 2 & 3 treatment costs 564,776 199,475 247,908
CIN Persistent 2 & 3 treatment costs 3,067,301 435,141 710,367
Genital warts treatment costs 3,094,714 3,094,714 335,580
Cervical cancer treatment costs 1,087,169 96,483 157,511
Life-years (LY) 1,692,651 1,695,651 1,695,338
QALYs 1,717,089 1,720,571 1,720,299
DISCOUNTED
Total costs 6,880,106 15,034,926 14,210,399
Life-years (LY) 711,164 711,800 711,734
QALYs 735,991 736,775 736,784
*In addition to screening
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Page 6 of 11Table 4 Sensitivity analysis for the imput parameters on ICER and Cost-Benefit
Parameters ICER (SGD/LY saved), discounted ICER (SGD/QALY saved), discounted Cost Benefit Analysis (million SGD),
discounted
Quadrivalent
vaccine vs
No vaccine
Bivalent
vaccine
vs No
vaccine
Bivalent
vaccine vs
Quadrivalent
vaccine
Quadrivalent
vaccine vs
No vaccine
Bivalent
vaccine
vs No
vaccine
Bivalent
vaccine vs
Quadrivalent
vaccine
Quadrivalent
vaccine vs
No vaccine
Bivalent
vaccine
vs No
vaccine
Bivalent
vaccine vs
Quadrivalent
vaccine
Base case 12,866 12,827 12,488 9,071 10,392 Dom 8.23 9.47 1.24
Vaccine coverage (base:100%) - assuming vaccine purchase costs for the cohort are sunk costs
20% 86,397 83,454 56,178 61,804 67,631 Dom -6.25 -6.57 -0.33
40% 40,444 39,322 29,109 28,847 31,864 Dom -2.72 -2.75 -0.03
60% 25,124 24,607 19,981 17,861 19,938 Dom 0.92 1.21 0.29
80% 17,464 17,246 15,337 12,367 13,973 Dom 4.67 5.23 0.63
Vaccine coverage (base:100%) - assuming vaccine costs are as consumed
20% 11,524 15,873 56,178 8,059 12,818 Dom 1.75 1.43 -0.33
40% 12,804 14,417 29,109 9,010 11,668 Dom 3.38 3.25 -0.03
60% 13,034 13,733 19,981 9,166 10,727 Dom 4,92 5.21 0.29
80% 13,003 13,241 15,337 9,185 11,122 Dom 6,67 7.3 0.63
Vaccine efficacy (Bivalent base: 88.3%, Quadrivalent base: 79.4%)
70% 15,008 17,237 Dom 10,369 13,894 Dom 6.43 5.31 -1.11
90% 10,863 12,326 Dom 7,733 9,932 Dom 11.13 10.17 -0.96
Vaccination costs (base: SGD$400 for both)
Decrease
to SGD
$300 for
both
8,521 8,942 12,572 5,922 7,205 Dom 10.96 11.96 1
Decrease
to SGD
$200 for
both,
4,109 4,988 12,572 2,775 4,019 Dom 13.46 14.46 1
Decrease
to SGD
$100 for
both
Dom 1,034 12,572 Dom 833 Dom 15.96 16.96 1
Booster (base: none)
5 years 91,149 83,707 19,486 67,830 70,487 Dom -36.07 -35.52 0.54
10 years 47,045 43,778 15,584 36,192 38,134 Dom -10.94 -10.14 0.8
20 years 27,321 26,048 15,067 19,483 21,093 Dom 0.3 1.13 0.84
Screening coverage rate (base: 17%)
10% 12,424 12,398 12,171 9,120 10,409 Dom 9.2 10.29 1.08
25% 13,670 13,558 12,593 9,199 10,552 Dom 7.68 8.63 0.95
40% 15,200 14,845 11,783 9,628 10,977 Dom 6.43 7.35 0.92
Effectiveness against viral warts
70% 13,348 12,827 8,996 9,665 10,392 57,447 8.23 9.46 1.23
80% 13,143 12,827 10,768 9,366 10,392 640,633 8.35 9.46 1.11
100% 12,721 12,827 14,408 8,777 10,392 Dom 8.59 9.46 0.86
Dom = Dominated by quadrivalent vaccine
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Page 7 of 11of the vaccination strategy. Conversely, overall ICER for
all comparisons increases and cost-benefit decreases
when vaccine waning and administering a booster in the
future are considered, although the vaccination strate-
gies are still cost-effective up to 10 yearly boosters.
Changing the cervical cancer screening rates through
pap smears affects the outcomes - increasing screening
coverage rates increases ICER and decreases cost-benefit
for vaccination due to the higher rates of early detection
of CIN states which can be treated before they develop
cancer. Increasing screening coverage also decreases the
cost per life year saved for the bivalent vaccine com-
pared to the quadrivalent vaccine because screening
reduces CIN cases and therefore the advantage that the
quadrivalent vaccine has in reducing the number of CIN
cases due to non-oncogenic HPV.
The ICER for the quadrivalent vaccine vs. no vaccine
increases with reduced effectiveness of the quadrivalent
vaccine against genital warts. At 100% effectiveness the
quadrivalent vaccine vs. no vaccine is more cost-effec-
tive compared to the bivalent vaccine vs. no vaccine
across all 3 measures. Changing the sensitivity of the
pap- smear tests, the compliance to treatment, or the
cost of the interventions does not change the outcome
substantially - vaccination remains cost-effective and
the bivalent vaccine remains the more cost-beneficial
strategy compared to the quadrivalent vaccine, and
more-cost effective per life year saved. However, when
using cost-per QALY saved, the quadrivalent vaccine
dominates the bivalent vaccine across the board due to
the additional QALYs saved from reducing genital
warts.
The results of the one-way sensitivity analysis on ICER
are shown in Figures 3 and 4. It is evident that the pri-
mary outcome is most affected by the vaccine effective-
ness and the percentage of vaccine coverage. This
means that vaccine parameters are the most important
factors in the overall outcomes. The probability of
infection with HPV, the probability of conversion from
HPV to CIN1, and the transition probabilities between
the CIN states and back to the well state also have
some impact on the outcome. This is likely due to the
importance of these parameters on the number of CIN
cases that require treatment, and the eventual number
of cancer cases. This also means that prevention of HPV
infection and CIN is important to reduce the impact
from the disease.
Discussion
During the last few decades, cervical cytology pro-
grammes have demonstrated their usefulness in redu-
cing cervical cancer mortality and morbidity in many
developed countries. However, it is a well-established
fact that to be successful in population-based cervical
screening, the coverage of the population screened must
be adequate and this has often proved difficult to
achieve. Although the incidence has declined over the
years, cervical cancer, which is a preventable cancer, is
still a common gynecological cancer in Singapore. With
the global arrival of HPV vaccines, vaccination may be a
successful complement to screening and decision on
adoption of HPV vaccination will need to be made
across individual countries.
The results of this study conclusively shows that
HPV vaccination is a cost effective strategy at the
population level, as the ICERs across most vaccination
strategies were much lower than the per-capita GDP
for Singapore, and the vaccine strategies were more
cost-beneficial under a wide range of circumstances.
This is similar to a recent study in Taiwan which
showed the cost-effectiveness of universal vaccination
of adolescent girls [51].
As a base case, the cost per life year saved for the
bivalent vaccine was slightly lower compared to the
quadrivalent vaccine, and the cost-benefit higher. At the
same time, the cost per QALY saved is slightly lower for
Figure 3 One-way sensitivity analysis tornado diagrams for the
quadrivalent vaccine
Figure 4 One-way sensitivity analysis tornado diagrams for the
bivalent vaccine
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cine. This is because the quadrivalent vaccine resulted
in benefits from reduction in genital warts and CIN, but
the bivalent vaccine increased life-years saved. Policy
makers will therefore have to consider these factors
(higher reduction in QALY versus more lives saved) in
choosing between the 2 vaccines, but either option is
much better than no vaccination at all.
The bivalent vaccine is most cost-beneficial at higher
vaccine coverage rates of >40%, while the quadrivalent
vaccine is more cost-effective and cost-beneficial at
lower coverage rates as the number of lives saved are
reduced. The quadrivalent vaccine also dominates the
bivalent vaccine in the absence of cross-reactivity against
non-16/18 oncogenic HPV types, due to the additional
reduction on genital warts. This is similar to another
study in Ireland which shows that the quadrivalent vac-
cine was more cost-effective assuming both vaccines
have similarly high protective efficacy against HPV [29].
Of interest, if vaccine purchases are a priori and are
sunk costs, the ICER increases substantially for both
vaccines as vaccine coverage decreases, and cost-benefit
decreases. Under this assumption, vaccine coverage of
≤40% would render vaccination not cost-effectiveness as
an overall strategy. It is therefore important for policy
makers rolling out universal vaccination strategies with
stockpiled vaccines to ensure sufficient vaccine uptake
to maintain high societal economic benefit, or to pur-
chase vaccines on an as required basis based on vaccina-
tion uptake.
In addition, the waning of immunity and additional
vaccinations contribute substantial to the vaccination
costs. Boosters at intervals of once every 20 years still
maintain the cost-effectiveness of vaccination. However,
more frequent boosters of less than 10 years render vac-
cination a non-cost-effective strategy. Waning of immu-
nity results in costs far greater compared to the absence
of cross-protection to non-16/18 oncogenic HPV types
or to genital warts. It is therefore more important for
vaccine manufacturers to increase the efficacy of their
vaccines in terms of long-term immunity.
This study does not take into account the dynamics of
viral transmission and thus underestimating the impact of
herd immunity. Transmission models that accounted for
herd immunity suggest that vaccination and screening
s t r a t e g yw o u l db em u c hm o r ea t t r a c t i v ec o m p a r e dt o
screening-only - Chesson et al [9] further demonstrated
that herd immunity could reduce ICER by 37.9%. In addi-
tion, women who adhere to previous cervical screening
tests may have better compliance with subsequent tests,
but with the lack of information in the local context, we
did not perform individual-based modelling. Also, the
model does not take into consideration the potential
reduction of other HPV-related cancers like
adenocarcinoma of the cervix, vulvar carcinoma or laryn-
geal papillomatosis. Indirect costs such as absence of work
or transportation costs for patients with cervical cancer
are also excluded. Given that this study did not include
herd immunity effects, we did not study the outcomes of
vaccinating boys or optimal catch-up strategies, and we
did not consider catch up vaccination, which could
increase the immediate benefits of vaccination programs.
Conclusions
We demonstrate that vaccination of adolescent girls, in
addition to current cytology-based screening, is a cost-
effective use of healthcare resources. The bivalent vac-
cine saves more lives compared to the quadrivalent vac-
cine, while the quadrivalent vaccine has lower cost per
QALYs saved compared to the bivalent vaccine. The
main advantage of vaccination will be to reduce cervical
cancer mortality but the full benefits of vaccination will
be observed 10-20 years after its introduction. Further
studies should focus on quantifying the duration of vac-
cine protection, and use dynamic models to examine the
efficiencies of different screening and vaccine strategies
in reducing HPV-related disease. Studies should also
focus on optimal synergies between screening and vacci-
nation and on affordability and equity in delivery.
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